top of page
Patient Story.jpg
spravato-patient-brochure_Page_01.png

See our SPRAVATO treatment areas.

Patient Story.jpg

SPRAVATO® helped Nicole’s treatment-resistant depression. Now, she’s sharing her story. 

SPRAVATO® 
Now at Three Strand Wellness

If you’ve taken two or more oral antidepressants and still experience symptoms of depression, you might have treatment-resistant depression (TRD).

Spravato-img2.jpg

It might be time to talk with us about a different treatment approach. See what makes SPRAVATO® different and learn more about other patients’ experiences with SPRAVATO®.

Adults with treatment-resistant depression who were part of a clinical study were given either a nasal esketamine spray or a placebo spray. Those who added esketamine, the active ingredient in SPRAVATO®, to their oral antidepressant experienced a greater reduction of depressive symptoms at four weeks compared to those who received placebo plus an oral antidepressant. (*Based on an overall score on a standardized rating scale.)

Ask the Experts.jpg

Doctors answer patients’ top questions about SPRAVATO®. Be sure to watch the entire video to get the full SPRAVATO® story, including safety information.

bottom of page